Abstract

In this electrochemical reduction method, CO2 is electrochemically reduced in a state where a solution having a pH of 5 to 15 and the CO2 have been brought into contact with a catalyst containing an oxide containing Ti.

IPC Classes  ?

• C25B 11/042 - Electrodes formed of a single material
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 3/26 - Reduction of carbon dioxide

Abstract

A plasmalogen production–promoting culture medium according to the present invention includes lactose as a carbon source and is to be used to culture lactic acid bacteria.

IPC Classes  ?

• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
• C12N 1/20 - Bacteria; Culture media therefor
• C12P 7/6427 - Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone

Abstract

Provided is an antifibrotic agent comprising a copolymer having a constituent unit (a) containing an N-acetylglucosamine group and a constituent unit (b) containing a structure represented by general formula (b) (excluding a constituent corresponding to the constituent unit (a)). In general formula (b), Yb represents a bivalent linking group containing an oxygen atom; Rb represents a hydrogen atom or an organic group; and * represents a bonding hand.

IPC Classes  ?

• A61K 31/795 - Polymers containing sulfur
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C08F 20/36 - Esters containing nitrogen containing oxygen in addition to the carboxy oxygen

Abstract

When ΔEST of at least one of a donor compound and an acceptor compound to form an exciplex is 0.35 eV or less, the driving lifetime of an exciplex light-emitting device can be improved.

IPC Classes  ?

• H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 85/60 - Organic compounds having low molecular weight

Abstract

There is provided a plasma processing apparatus for performing plasma processing on a substrate, comprising: a processing container accommodating the substrate; an electrode to which a high-frequency power for generating plasma in the processing container is applied; a high-frequency power supply configured to apply the high-frequency power to the electrode; and a high-frequency power supply circuit configured to supply the high-frequency power from the high-frequency power supply to the electrode. The high-frequency power supply circuit comprises: a power supply path configured to supply a power from the high-frequency power supply to the electrode; and a matching device configured to match a high-frequency power supply-side impedance with a plasma-side impedance, the matching device comprising a negative impedance portion that is connected to the power supply path and realizes a negative impedance corresponding to a plasma-side impedance.

IPC Classes  ?

• H01J 37/32 - Gas-filled discharge tubes
• H03H 11/44 - Negative impedance converters

Abstract

The present invention relates to a method for preparing a double-stranded DNA library from single-stranded DNA fragments and provides a highly efficient library preparation method, etc., that generates or contains few adapter dimers. The present invention is a method for preparing a double-stranded DNA library from single-stranded DNA fragments that includes the specific steps (i) to (v).

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12Q 1/6869 - Methods for sequencing
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof

Abstract

A heat transfer member (1) comprises: a base material (2) that comprises an inorganic compound containing a metallic element or a metal; and an oxide layer (3) that comprises an oxide of the metallic element contained in the base material (2) and that is formed on the base material (2). The oxide layer (3) has a plurality of pores (31) each provided with: a first part (312) which has an opening (311) in a surface of the heat transfer member (1) and in which the average opening diameter of the opening (311) is 5-70 nm; and a second part (313) which is connected to the first part (312) and in which the average pore diameter is greater than the average opening diameter of the first part (312). The average depth of the second part (313) is not less than 600 nm and not more than 20 μm.

IPC Classes  ?

• C25D 11/12 - Anodising more than once, e.g. in different baths
• C25D 11/04 - Anodisation of aluminium or alloys based thereon
• F28F 13/02 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by influencing fluid boundary
• H01L 23/427 - Cooling by change of state, e.g. use of heat pipes

Abstract

Provided is a carbonyl sulfide production method that can produce carbonyl sulfide with a good yield using a gas-phase flow method and without using a catalyst. This method for producing carbonyl sulfide comprises: a step for exciting, in hot plasma, a crude gas comprising a starting substance containing carbon atoms, sulfur atoms, and oxygen atoms; and a step for cooling the crude gas excited by plasma.

IPC Classes  ?

• C01B 32/77 - Carbon oxysulfide

Abstract

A method according to the present invention is a method for predicting the therapeutic effect of pharmacotherapy in the treatment of a subject with metastatic prostate cancer, wherein the pharmacotherapy includes at least one selected from among androgen deprivation therapy, androgen receptor deprivation therapy, and an anticancer drug, and said method includes a step for detecting the presence or absence of at least one single nucleotide polymorphism in the subject.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Provided are: a bipolar membrane electrodialyzer which has a high electric-current efficiency and in which the cation-exchange membrane is inhibited from suffering scale deposition therein due to divalent cations; and a method for operating the bipolar membrane electrodialyzer.　The method is for operating a bipolar membrane electrodialyzer configured of a bipolar membrane, a cation-exchange membrane, and an anion-exchange membrane, the method comprising using the bipolar membrane electrodialyzer to yield an acid and an alkali from brine and being characterized by conducting electrodialysis while regulating the acid solution and/or the alkali solution so as to contain a salt to be decomposed.

IPC Classes  ?

• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
• B01D 61/44 - Ion-selective electrodialysis
• B01D 61/46 - Apparatus therefor

Abstract

Provided are a production method and a production system of calcium carbonate that utilize a calcium-containing waste and can control the alkali content in the obtained calcium carbonate.　The calcium carbonate production method for producing calcium carbonate from a calcium-containing waste includes: a calcium dissolution step for adding an aqueous hydrochloric acid solution to the calcium-containing waste and dissolving calcium to prepare an aqueous solution containing calcium ions; a separation step for adjusting the hydrogen ion concentration index of the aqueous solution containing calcium ions to separate Mg, etc. from the aqueous solution; and a calcium carbonate preparation step for adding an aqueous solution containing potassium carbonate and/or sodium carbonate to the aqueous solution containing calcium ions obtained in the separation step and reacting to prepare calcium carbonate. In this calcium carbonate production method (system), in the calcium carbonate preparation step, the rate of the addition of the aqueous solution containing potassium carbonate and/or sodium carbonate is controlled so as to adjust κ, which is represented by a specific formula, to 3000 or less.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation

Abstract

The present invention provides candidate molecules for constituent components of various lipid nanoparticles.　The present invention pertains to a C-glycoside glycolipid compound represented by formula (I) or formula (II), a lipid nanoparticle containing the same, and a pharmaceutical composition containing the lipid nanoparticles, particularly a vaccine.

IPC Classes  ?

• C07D 309/10 - Oxygen atoms
• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 37/04 - Immunostimulants
• C07H 17/04 - Heterocyclic radicals containing only oxygen as ring hetero atoms
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

Provided is a method for enabling recovery of metal element leaching capacity of a deep eutectic solvent used for leaching a metal element from an ore containing the metal element. A method for recycling a hydrophobic deep eutectic solvent disclosed here includes: preparing a hydrophobic deep eutectic solvent used for leaching a metal element from an ore containing the metal element; and bringing the hydrophobic deep eutectic solvent and hydrochloric acid into contact with each other. In the hydrophobic deep eutectic solvent, a hydrogen bond donor is a carboxy group-containing compound, and a hydrogen bond acceptor is chloride salt. The amount of use of the hydrochloric acid is such that hydrogen chloride is 1 mole or more with respect to 1 mole of the hydrogen bond acceptor.

IPC Classes  ?

• C09K 13/00 - Etching, surface-brightening or pickling compositions
• C01G 53/10 - Sulfates
• C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes
• C22B 3/04 - Extraction of metal compounds from ores or concentrates by wet processes by leaching
• C22B 3/10 - Hydrochloric acid
• C22B 3/14 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in inorganic alkaline solutions containing ammonia or ammonium salts
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions

Abstract

This protein comprises an amino acid sequence selected from the group consisting of amino acid sequences (a), (b), (c) and (d) and has a plasmalogen synthesis activity in a bacterium that expresses the protein. (a) The amino acid sequence represented by SEQ ID NO:1; (b) an amino acid sequence which has 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO:1; (c) the amino acid sequence represented by SEQ ID NO:2; and (d) an amino acid sequence which has 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO:2.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats

Abstract

Provided are an introduction device and a delivery method that are applicable to various types of cells and capable of delivering a target substance, even including a large molecule, to cells at a high efficiency. The introduction device and the method for delivering a target substance to cells using the introduction device, said introduction device being equipped with a bubble generation unit 20, a counter electrode 40 and a power supply unit 50 connected respectively to the bubble generation unit and the counter electrode. The bubble generation unit 50 comprises a core material 21 made of a conductive material and forming an active electrode, and a tubular member 22 made of an insulating material and extending along the core material to cover around the core material. The tip of the tubular member 22 is substantially on the same plane as the tip of the core material 21, or extends beyond the tip of the core material 21. The bubble generation unit 20 is configured to generate bubbles from the tip of the bubble generation unit 20 when a voltage is applied to the active electrode from the power supply unit in the state where the tip of the bubble generation unit 20 and the counter electrode 40 are in contact with a liquid containing the cells and the target substance.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 15/09 - Recombinant DNA-technology

Abstract

A nucleic acid fragment including a polymerase binding sequence and a transposase binding sequence, in which the polymerase binding sequence or the transposase binding sequence contains a caged nucleotide residue; a specific binding substance; a method for binding a polymerase or a transposase to the nucleic acid fragment; a method for inserting the nucleic acid fragment in a vicinity of a binding region of a DNA-binding protein bound to a DNA molecule; and a method for gene-amplifying the DNA molecule into which the nucleic acid fragment is inserted are provided.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6804 - Nucleic acid analysis using immunogens

Abstract

Provided is a drug for preventing or treating heart failure, that is effective and that does not have a blood pressure lowering effect.　The present invention pertains to: a pharmaceutical composition for preventing or treating heart failure or skeletal muscle failure, the pharmaceutical composition containing a TRPC3/6/7 channel activator; and a related screening method.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/05 - Phenols
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

The present invention relates to a compound represented by formula (I) (in the formula, R1is a C1-4 alkyl group or the like, and A1and A2are each independently a group, etc. represented by formula (II), in which R2and R3 are each independently a hydrogen atom, a C1-4 alkyl group, or the like, and * is a bonded section), a light-emitting material containing said compound, and a light-emitting element containing said light-emitting material.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 50/10 - OLEDs or polymer light-emitting diodes [PLED]

Abstract

An object of the present invention is to provide an apparatus for injecting carbon dioxide into underground capable of capturing carbon dioxide from the atmosphere and injecting it into underground in a harmless state and at a low cost, the apparatus including: a capturing unit configured to concentrate carbon dioxide directly from the atmosphere and capture concentrated carbon dioxide as a mixture gas; and an injection well connected to the capturing unit for pressurizing the mixture gas and injecting the mixture gas into an underground reservoir, in which the capturing unit adjusts a proportion of carbon dioxide in the mixture gas to 25% by volume or more.

IPC Classes  ?

• E21B 41/00 - Equipment or details not covered by groups
• B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion

Abstract

The present invention provides a compound for treating or preventing reduced intracellular ATP levels.　The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition that contains the compound or the pharmaceutically acceptable salt or solvate thereof. [In the formula, X and Y are the same or different and are each selected from among substituent group A, which is groups represented by formula 1: -O-R1 (in the formula, R1 is selected from among hydrogen, C1–8 alkyl groups, C1–3 alkyl aryl groups, CH3OCH2-, CH3OCH2CH2-, ester groups, phenyl groups, pyridyl groups, benzyl groups, indolyl groups, and naphthyl groups, and any aromatic rings or heterocyclic rings may be substituted with one to three functional groups) when the atom connected to the phosphorus atom is O, or substituent group B, which is groups represented by formula 2: -R2-R3 (in the formula, R2 is a residue generally described as an amino carboxylic acid, and R3 is a substituent bonded to the carboxylic acid portion of the amino carboxylic acid of R2) when the atom connected to the phosphorus atom is N.]

IPC Classes  ?

• C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Abstract

123411 represents triphenyl phosphine, pyridine, imidazole, dimethyl sulfoxide or water; X represents a monovalent group that is obtained by removing a hydrogen atom from a carboxyl group of a carboxylic acid; X- represents an anion of the carboxylic acid; and n represents 1 or 2.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
• B01J 31/24 - Phosphines
• B01J 37/04 - Mixing
• C07C 45/28 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of —CHx-moieties
• C07C 49/403 - Saturated compounds containing a keto group being part of a ring of a six-membered ring
• C07C 67/29 - Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
• C07C 69/14 - Acetic acid esters of monohydroxylic compounds
• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• C07C 69/78 - Benzoic acid esters
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 205/57 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 227/16 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
• C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
• C07C 303/40 - Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
• C07C 311/19 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
• C07B 61/00 - Other general methods

Abstract

An organic light-receiving element includes an organic light-receiving layer containing a plurality of organic semiconductor molecules. Each of the plurality of organic semiconductor molecules is a molecule in which an excited state enabling reverse intersystem crossing from a lowest excited triplet state to a lowest excited singlet state is formed in each of the plurality of organic semiconductor molecules due to irradiation with light.

IPC Classes  ?

• H10K 30/20 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising organic-organic junctions, e.g. donor-acceptor junctions

Abstract

A biomolecule structure detection probe, wherein a specific binding substance having a specific binding activity to a biomolecule structure is linked to a labeling substance via a linker including a disulfide bond. In addition, a biomolecule structure detection kit including the biomolecule detection probe and a reagent for cleaving the disulfide bond. In addition, a biomolecule structure detection kit including a linker for linking a specific binding substance having a specific binding activity to a biomolecule structure with a labeling substance, the linker including a disulfide bond; and a labeling substance capable of being bonded to the linker; and a reagent for cleaving the disulfide bond. In addition, a method for detecting a biomolecule structure using the biomolecule structure detection probe.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

A method for designing a protein capable of binding in an RNA base selective manner or RNA base sequence specific manner is provided. The protein of the present invention is a protein containing one or more of PPR motifs (preferably 2 to 14 PPR motifs) each consisting of a polypeptide of 30- to 38-amino acid length represented by the formula 1 (wherein Helix A is a moiety of 12-amino acid length capable of forming an α-helix structure, and is represented by the formula 2, wherein, in the formula 2, A1 to A12 independently represent an amino acid; X does not exist, or is a moiety of 1- to 9-amino acid length; Helix B is a moiety of 11- to 13-amino acid length capable of forming an α-helix structure; and L is a moiety of 2- to 7-amino acid length represented by the formula 3, wherein, in the formula 3, the amino acids are numbered “i” (−1), “ii” (−2), and so on from the C-terminus side, provided that Liii to Lvii may not exist), and combination of three amino acids A1, A4 and Lii, or combination of two amino acids A4, and Lii is a combination corresponding to a target RNA base or base sequence.

IPC Classes  ?

• G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
• G16C 20/60 - In silico combinatorial chemistry
• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• G16B 20/50 - Mutagenesis
• G16B 20/30 - Detection of binding sites or motifs
• G16B 30/10 - Sequence alignment; Homology search
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Provided is a novel polymer compound containing a chain ether structure and exhibiting bioaffinity.　The polymer compound has a polyolefin skeleton as a main chain and a structure including a chain ether structure introduced into a side chain part thereof.

IPC Classes  ?

• C08F 8/02 - Alkylation
• C08F 16/16 - Monomers containing no hetero atoms other than the ether oxygen
• C09D 129/10 - Homopolymers or copolymers of unsaturated ethers

Abstract

This flotation recovery rate prediction device, for predicting the recovery rate of a metal subject to sorting in flotation sorting in which the metal subject to sorting is separated from an ore in which a plurality of ores containing a plurality of minerals are mixed, comprises: a receiving unit for receiving a desired recovery rate of the metal subject to sorting; an acquisition unit for acquiring information representing the relationship between soluble metal ratio and mineral content, and information representing the recovery rate of the metal subject to sorting and the mineral content of each of the ores; a calculation unit for calculating, on the basis of the information representing the relationship between soluble metal ratio and mineral content and the information representing the recovery rate of the metal subject to sorting and the mineral content of each of the ores, the mixing ratio of the ores to achieve the desired recovery rate of the metal subject to sorting; and an output unit for outputting information indicating the calculated mixing ratio of the ores.

IPC Classes  ?

• E21C 41/22 - Methods of underground mining; Layouts therefor for ores, e.g. mining placers

Abstract

The present invention provides a compound for treating or preventing diseases caused by mitochondrial hyperfission. The present invention provides a compound for treating or preventing diseases caused by mitochondrial hyperfission. The present invention provides a compound represented by formula (1): The present invention provides a compound for treating or preventing diseases caused by mitochondrial hyperfission. The present invention provides a compound represented by formula (1): wherein R1 and R1′ are each independently hydrogen, an optionally substituted lower alkyl, an optionally substituted lower cycloalkyl, and the like; R2 is an optionally substituted lower alkyl, an optionally substituted lower cycloalkyl, and the like; R3 and R4 are each independently hydrogen, halogen, hydroxy, nitro, cyano, an optionally substituted lower alkyl, and the like; R5 and R6 are each independently an optionally substituted lower alkyl; an optionally substituted lower cycloalkyl, and the like; X is nitrogen or oxygen; Y is carbon, nitrogen or oxygen; and a broken line represents the presence or absence of a bond; or a pharmaceutically acceptable salt, a solvate, or a prodrug thereof.

IPC Classes  ?

• C07D 213/82 - Amides; Imides in position 3
• C07D 471/04 - Ortho-condensed systems
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 211/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 213/80 - Acids; Esters in position 3

Abstract

An object of the present invention is to provide a novel agent capable of activating SIRT6. A sirtuin 6 activator containing a urolithin as an active ingredient.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones

Abstract

The present invention provides a copolymer compound having a new property through compounding a polymer comprising a (meth)acrylic skeleton and/or a (meth)acrylamide skeleton with a structure different from the primary structure of the polymer.　Provided is a polymer compound comprising a (meth)acrylic skeleton and/or a (meth)acrylamide skeleton, wherein a side chain comprising a phosphonic acid group is introduced as a part of a side chain of the polymer compound.

IPC Classes  ?

• C08F 220/28 - Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
• C08F 220/10 - Esters
• C08F 220/56 - Acrylamide; Methacrylamide
• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08F 230/02 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium, or a metal containing phosphorus
• C08L 33/04 - Homopolymers or copolymers of esters
• C08L 33/24 - Homopolymers or copolymers of amides or imides
• C08L 43/02 - Homopolymers or copolymers of monomers containing phosphorus
• C09D 133/04 - Homopolymers or copolymers of esters
• C09D 133/24 - Homopolymers or copolymers of amides or imides
• C09D 143/02 - Homopolymers or copolymers of monomers containing phosphorus

Abstract

It was found that four nuclease domain mutants have nuclease activity superior to that of a wild-type nuclease domain and are capable of enhancing genome editing efficiency in combination with various nucleic acid binding domains.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

To provide a metal-containing additive and a crosslinkable polymer composition that each contain a β-diketonato metal complex and have excellent storage stability, and provide a crosslinked polymer material, a metal member, and a wire harness that are each produced using such a crosslinkable polymer composition. The metal-containing additive includes the β-diketonato metal complex and a primary alkyl alcohol having 4 to 30 carbon atoms. The crosslinkable polymer composition includes the metal-containing additive and an organic polymer, where the organic polymer has a substituent capable of forming ionic bonds with metal ions released by heat from the metal-containing additive.

IPC Classes  ?

• C08K 5/00 - Use of organic ingredients
• C08K 5/05 - Alcohols; Metal alcoholates
• C09D 7/63 - Additives non-macromolecular organic
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/28 - Protection against damage caused by external factors, e.g. sheaths or armouring by moisture, corrosion, chemical attack or weather

Abstract

A crosslinkable polymer composition and a crosslinked polymer material including a metal member and a wiring harness. The crosslinkable polymer composition contains component A from which metal ion is released by heat, component B containing an organic polymer having a substituent capable of ionic bonding with the metal ion released from component A, and component C containing one or more acidic phosphate ester with a carbon number of 4 to 30. Assuming that the metal ion released from component A has a valence of +y and a content of the metal ion is m mol, the substituent contained in component B has a valence of −z and a content of the substituent is n mol, the acidic phosphate constituting component C has a valence of −x and a content of the acidic phosphate esters is 1 mol A crosslinkable polymer composition and a crosslinked polymer material including a metal member and a wiring harness. The crosslinkable polymer composition contains component A from which metal ion is released by heat, component B containing an organic polymer having a substituent capable of ionic bonding with the metal ion released from component A, and component C containing one or more acidic phosphate ester with a carbon number of 4 to 30. Assuming that the metal ion released from component A has a valence of +y and a content of the metal ion is m mol, the substituent contained in component B has a valence of −z and a content of the substituent is n mol, the acidic phosphate constituting component C has a valence of −x and a content of the acidic phosphate esters is 1 mol g≥0.1 holds for g=(m·y−l·x)/(n·z).

IPC Classes  ?

• C09D 5/08 - Anti-corrosive paints
• C09D 147/00 - Coating compositions based on homolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Coating compositions based on derivatives of such polymers
• C09D 133/08 - Homopolymers or copolymers of acrylic acid esters
• C09D 183/04 - Polysiloxanes
• H01B 7/28 - Protection against damage caused by external factors, e.g. sheaths or armouring by moisture, corrosion, chemical attack or weather
• H01B 7/29 - Protection against damage caused by external factors, e.g. sheaths or armouring by extremes of temperature or by flame

Abstract

The subject's brain neurogenesis promoter of the present invention contains miR-30a, etc. or a vector which is for expressing miR-30a, etc. in the brain nerves of young and elderly subjects. The present invention also provides an agent for improving higher nervous function, an agent for improving memory learning function, a method for promoting brain neurogenesis, a method for improving higher nervous function, and a method for improving memory learning function. In the subject's brain neurogenesis promoter, etc. of the present invention, the subject may be an elderly subject.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 35/76 - Viruses; Subviral particles; Bacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention provides a composition to be used for attenuating skin barrier, said composition containing an anionic long-chain lipid (in particular, a long-chain fatty acid). The present invention provides a dispersion in which a complex (for example, a solid complex) comprising a cationic long-chain lipid, an anionic long-chain lipid and a drug is dispersed.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/08 - Solutions
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 17/00 - Drugs for dermatological disorders
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The purpose of the present invention is to provide a low-production-cost and low-loss optical element. Provided are an optical element (100) and a method for producing the optical element (100), the optical element (100) having a core (2) and a cladding comprising an undercladding (4) and an overcladding (3) on a substrate (1), wherein the core (2) includes a membrane structure (21) in at least a leading end region (31), includes a thin line structure (22) in an inner portion away from a leading end (P1) of the membrane structure (21) in a length direction, and has a stacking region (32) in which the membrane structure (21) and the thin line structure (22) overlap adjacent to each other in a thickness direction, a width (W1) at the leading end (P1) of the membrane structure (21) is wider than the width in the stacking region (32) of the thin line structure (22), and the materials of the membrane structure (21) and the thin line structure (22) included in the core (2) have substantially the same refractive index.

IPC Classes  ?

• G02B 6/122 - Basic optical elements, e.g. light-guiding paths
• G02B 6/13 - Integrated optical circuits characterised by the manufacturing method
• G02B 6/30 - Optical coupling means for use between fibre and thin-film device

Abstract

This composite conductive material includes: a main phase that includes a crystalline phase having a double perovskite crystalline structure; and particles that each project from the surface of the main phase and that each contain an oxide of a metal element occupying the B site of the crystalline phase.

IPC Classes  ?

• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• C01G 51/00 - Compounds of cobalt
• C01G 53/00 - Compounds of nickel
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances
• H01B 1/08 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances oxides
• H01M 4/88 - Processes of manufacture
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte

Abstract

An oral vaccine composition against a porcine circovirus-related disease, the oral vaccine composition comprising a pupa or a cell of a baculovirus infectious insect that has been subjected to an infection treatment with a recombinant baculovirus into which a DNA encoding a porcine circovirus type 2 protein has been introduced and subjected to a freeze-drying treatment.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 31/20 - Antivirals for DNA viruses
• A61P 37/04 - Immunostimulants
• A61P 17/00 - Drugs for dermatological disorders
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/34 - Proteins from DNA viruses
• C12N 15/86 - Viral vectors
• C12N 15/866 - Baculoviral vectors
• A61K 38/02 - Peptides of undefined number of amino acids; Derivatives thereof
• A61K 35/64 - Insects, e.g. bees, wasps or fleas

Abstract

Provided is, for example, a DNA methyltransferase that can recognize and methylate a short context other than a CG dinucleotide sequence in which endogenous methylation occurs, the short context being comparable to the CG dinucleotide sequence. The present invention pertains to a protein or the like in which some amino acid residues including the N terminal of a DNA methyltransferase of M.CviQIX or M.CviPII have been deleted, and activity of specifically recognizing a CC dinucleotide sequence and 5-methylating a cytosine residue of the 5' side in the sequence is acquired.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 15/54 - Transferases (2)
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C12N 9/10 - Transferases (2.)

Abstract

An information processing device, for communicating with an autonomous mobile device, includes circuitry and a memory storing computer-executable instructions that cause the circuitry to execute transmitting an operation command of an operator of the autonomous mobile device to the autonomous mobile device existing in a real world and a virtual mobile device simulating the autonomous mobile device and existing in a virtual world simulating the real world, and switching from a real mode to a virtual mode when the autonomous mobile device detects an inhibitor inhibiting operability of the operator to operate the autonomous mobile device, the real mode providing the operator with sensory feedback corresponding to an autonomous movement of the autonomous mobile device in the real world, and the virtual mode providing the operator with sensory feedback corresponding to a movement according to the operation command of the virtual mobile device in the virtual world.

IPC Classes  ?

• G05D 1/00 - Control of position, course, altitude, or attitude of land, water, air, or space vehicles, e.g. automatic pilot
• G05D 1/02 - Control of position or course in two dimensions

Abstract

Provided is a plant sensor device that is capable of suppressing the influence of outside light in the surrounding environment to quantify the growth degree of a plant and obtaining a parameter related to the amount of foliage of the plant using a simple and low-cost configuration. A plant sensor device 100 comprising a light source 11 that intermittently irradiates a plant with near-infrared (NIR) light, a radiation sensor 21 that is disposed on the opposite side of the light source 11 with respect to the plant and outputs output values obtained by photoelectrical conversion of the received transmitted NIR light having transmitted through the plant, and a recording unit 31 that records the output values from the radiation sensor 21, wherein the recording unit 31 records the irradiation period and the quenching period of the near-infrared light at light source 11, and the recording unit 31 classifies the output values from the radiation sensor into (1) NIR output values during the irradiation period of the near-infrared light and (2) non-irradiation output values during the quenching period of the near-infrared light; and an active optical measurement method of plant.

IPC Classes  ?

• A01G 7/00 - Botany in general

Abstract

The present disclosure addresses the problem of providing at least a technology for enhancing the expression of SIRT3 genes. Said problem is solved by a composition for enhancing SIRT3 gene expression, the composition containing urolithin M3 as an active ingredient.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61P 17/18 - Antioxidants, e.g. antiradicals
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/16 - Otologicals
• A61P 39/06 - Free radical scavengers or antioxidants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/08 - Anti-ageing preparations
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The present invention addresses the problem of providing a medicine for treating cardiovascular disease associated with inflammation of the cardiovascular system related to IL-6 and/or IL-1β. The present invention relates to an IL-6 and/or IL-1β inhibitor comprising a compound represented by formula (I) (in the formula, each symbol is as described in the specification.) or a pharmaceutically acceptable salt thereof. The present invention also relates to a medicine for treating cardiovascular disease associated with inflammation of the cardiovascular system related to IL-6 and/or IL-1β that contains as an active ingredient the abovementioned compound or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/10 - Antioedematous agents; Diuretics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• A61P 9/12 - Antihypertensives
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A machine learning method includes acquiring image data generated from reflected light of illumination light radiated to a first region of a semiconductor film on a substrate, the first region annealed by pulse laser light, acquiring data on a measured semiconductor property of the first region, generating training data including the image data as input and the measured data as output associated with each other, and performing machine learning using a neural network based on the training data to generate a learned model.

IPC Classes  ?

• H01L 21/67 - Apparatus specially adapted for handling semiconductor or electric solid state devices during manufacture or treatment thereof; Apparatus specially adapted for handling wafers during manufacture or treatment of semiconductor or electric solid state devices or components
• H01L 21/268 - Bombardment with wave or particle radiation with high-energy radiation using electromagnetic radiation, e.g. laser radiation
• H01L 21/687 - Apparatus specially adapted for handling semiconductor or electric solid state devices during manufacture or treatment thereof; Apparatus specially adapted for handling wafers during manufacture or treatment of semiconductor or electric solid state devices or components for supporting or gripping using mechanical means, e.g. chucks, clamps or pinches
• G06N 3/08 - Learning methods

Abstract

Provided are an emission material and an organic EL device including the emission material and having high emission efficiency and a long lifetime. An organic EL device comprising light emitting layers between an anode and a cathode opposite to each other; wherein at least one of the light emitting layers contains, as a light emitting dopant, a compound in which a backbone having a specific 5-ring-fused ring structure, and a boron atom are combined, and the compound is represented by the following general formula (1). Provided are an emission material and an organic EL device including the emission material and having high emission efficiency and a long lifetime. An organic EL device comprising light emitting layers between an anode and a cathode opposite to each other; wherein at least one of the light emitting layers contains, as a light emitting dopant, a compound in which a backbone having a specific 5-ring-fused ring structure, and a boron atom are combined, and the compound is represented by the following general formula (1).

IPC Classes  ?

• H10K 85/60 - Organic compounds having low molecular weight
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

This vibration analysis method is a method for analyzing vibrations of a large-scale system with local strong nonlinearities, and includes a process (1) of applying the new type of complex modal analysis to an equation for a linear state variable to convert the equation to a real modal equation for lower-order modes, and correcting an effect of higher-order modes of the linear state variable from an equation for a nonlinear state variable and eliminating the modes, a process (2) of selecting secondary modes, which have a large effect on a solution of an original large-scale system, from the real modal equation for lower-order modes, and, in relation to secondary modes, which have a small effect, eliminating the modes thereof by incorporating the effect to the equation for nonlinear state variables as a correction term obtained from an approximate solution of the real modal equation for lower-order modes, and deriving the dimension reduced model, and a process (3) of calculating a frequency response by using the dimension reduced model.

IPC Classes  ?

• G01M 5/00 - Investigating the elasticity of structures, e.g. deflection of bridges or aircraft wings

Abstract

A thermally conductive additive is excellent in thermal conductivity improvement effect and has high processability, and a thermally conductive composite material and a wire harness each contain such a thermally conductive additive. The thermally conductive additive includes an organic component and a metal-containing component, where the organic component is configured as an organic compound including a coordination part that can multidentate-coordinate to a metal, and at least one functional group bonded to the coordination part and having a conjugated π-electron system, and the organic component coordinates in the coordination part to a metal atom constituting the metal-containing component to form a coordination complex. The thermally conductive composite material includes the thermally conductive additive and a matrix material, where the thermally conductive additive is dispersed in the matrix material. The wire harness includes the thermally conductive composite material.

IPC Classes  ?

• C09K 5/14 - Solid materials, e.g. powdery or granular
• C09C 1/02 - Compounds of alkaline earth metals or magnesium
• C09C 3/08 - Treatment with low-molecular-weight organic compounds
• C08K 5/00 - Use of organic ingredients
• C08K 9/04 - Ingredients treated with organic substances
• C07C 49/78 - Acetophenone
• C07C 49/84 - Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
• C07C 49/213 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings
• C07C 49/825 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
• C07C 49/83 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
• C07C 49/14 - Acetylacetone, i.e. 2,4-pentanedione
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/42 - Insulated conductors or cables characterised by their form with arrangements for heat dissipation or conduction

Abstract

A thermally conductive filler can exhibit high thermal conductive properties with a reduced specific gravity, a thermally-conductive composite material and a wire harness contains such a thermally conductive filler, and a method manufactures a thermally conductive filler. A thermally conductive filler contains base particles and a coating layer coating the particles, the coating layer contains a gel-like substance that is bonded to the surfaces of the base particles through chemical bonding and coats the surfaces of the base particles, and a thermally-conductive substance that is dispersed in the layer of the gel-like substance and has a higher thermal conductivity and a larger specific gravity than the base particles and the gel-like substance. Also, a thermally-conductive composite material is obtained by dispersing the thermally conductive filler in a matrix material. Furthermore, a wire harness contains the thermally-conductive composite material.

IPC Classes  ?

• C09K 5/14 - Solid materials, e.g. powdery or granular
• C08K 9/02 - Ingredients treated with inorganic substances
• C08K 7/28 - Glass
• C08K 7/06 - Elements
• C03C 17/32 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with organic material with synthetic or natural resins
• C03C 17/00 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating

Abstract

There is provided a copper alloy bonded body composed of a plurality of members made of an age-hardenable copper alloy, the members diffusion-bonded to one another. The copper alloy bonded body has undergone solution annealing and an aging treatment, the content of beryllium in the age-hardenable copper alloy is 0.7% by weight or less, and (i) a bonding interface between the members has disappeared and/or (ii) a bonding interface between the members remains, and an oxide film at the bonding interface has a thickness of 0 nm or more and 5.0 nm or less.

IPC Classes  ?

• C22C 9/06 - Alloys based on copper with nickel or cobalt as the next major constituent
• C22F 1/02 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working in inert or controlled atmosphere or vacuum
• C22C 9/00 - Alloys based on copper
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• B23K 20/02 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating by means of a press
• C22F 1/08 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of copper or alloys based thereon
• B32B 15/01 - Layered products essentially comprising metal all layers being exclusively metallic

Abstract

This disease state assessment kit for Rett syndrome comprises a reagent for detecting a gene contained in the mitochondrial genome in a sample collected from a subject.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The purpose of the present invention is to provide a novel composition for improving brain function and a novel composition for promoting the production of brain-derived neurotrophic factor (BDNF). The present invention provides a composition for maintaining and/or improving brain function that contains isovaleraldehyde as an active ingredient. The present invention also provides a composition for promoting the production of brain-derived neurotrophic factor (BDNF) that contains isovaleraldehyde as an active ingredient. The aforesaid compositions are preferably food compositions, feed compositions or pharmaceutical compositions.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 20/105 - Aliphatic or alicyclic compounds
• A61K 31/11 - Aldehydes
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 15/12 - Genes encoding animal proteins

Abstract

This blast state evaluation device evaluates the blast rate after a blast treatment on a surface to be examined of a structure, the device including: an irradiation unit 11 that irradiates the surface to be examined with measurement light; a detection unit 12 that detects reflected light from the surface to be examined that has been irradiated with the measurement light; and an evaluation unit 22 serving as an analysis unit that estimates the blast rate on the surface to be examined on the basis of the intensity of light of a specific wavelength included in the reflected light detected at the detection unit 12.

IPC Classes  ?

• G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01B 11/30 - Measuring arrangements characterised by the use of optical techniques for measuring roughness or irregularity of surfaces

Abstract

722Fe particles and the like.

IPC Classes  ?

• C22C 21/10 - Alloys based on aluminium with zinc as the next major constituent
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• C22F 1/04 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon

Abstract

The present invention improves the physical properties of a polymer that includes an alkoxy alkyl (meth)acrylate as a principal structural unit to achieve a polymer that has physical properties that are very similar to a biological substance. The present invention provides a copolymer that includes as structural units (A) a hydroxy alkyl (meth)acrylate and/or an alkoxy alkyl (meth)acrylate and (B) a monomer that has a host group.

IPC Classes  ?

• C08F 220/22 - Esters containing halogen
• C08F 220/26 - Esters containing oxygen in addition to the carboxy oxygen
• C08F 220/28 - Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08L 33/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
• C08L 33/26 - Homopolymers or copolymers of acrylamide or methacrylamide
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/20 - Polysaccharides
• A61L 27/50 - Materials characterised by their function or physical properties

Abstract

An object of the present disclosure is at least to provide a technique for enhancing expression of a NAMPT gene. The object is achieved by a composition for enhancing NAMPT gene expression, the composition containing an equol compound as an active ingredient.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin

Abstract

The present invention addresses the problem of clarifying the relation between environmental stress and seed quality and improving the yield and quality of a crop seed by a new method different from conventional gene engineering methods. Provided are: a plant seed having a promotor in which the methylation level of any gene selected from the group consisting of gene SLB1, gene Hd1, gene AGPS2b, gene GBSSI, gene SuSy2, gene AMy1A, and gene Amy3D is effectively controlled, and a product of the plant seed; and a harvest obtained therefrom and a processed product of the harvest. Also provided is a method for producing a plant seed having useful characteristics, the production method involving: a step for culturing a first generation plant under environmental stress; and a step for obtaining, from the cultured plant or an offspring thereof, a seed memorizing the environmental stress.

IPC Classes  ?

• A01H 3/00 - Processes for modifying phenotypes
• A01H 5/10 - Seeds
• C12N 15/09 - Recombinant DNA-technology
• A01G 7/00 - Botany in general
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize

Abstract

Provided is a polymer composition that exhibits sufficient biocompatibility and is capable of suppressing the elastic modulus, which is the source of elastic force that is generated by deformation.　Provided is a polymer composition containing a polymer that has a (meth)acrylate backbone and that contains, at the side chain segment relative to this backbone, repeating units having a propylene glycol structure in which the number of repetitions is at least four.

IPC Classes  ?

• C08F 20/06 - Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
• C09D 133/04 - Homopolymers or copolymers of esters

Abstract

The object of the present invention is to provide an inexpensive and effective sirtuin activator derived from natural products. The object of the present invention is to provide an inexpensive and effective sirtuin activator derived from natural products. The problem can be solved by a sirtuin activator comprising β-alanine or a salt thereof, or a composition for activating sirtuin comprising the sirtuin activator as an active ingredient, of the present invention.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
• A61P 17/00 - Drugs for dermatological disorders
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Provided is a thermally activated delayed fluorescence organic EL device having high emission efficiency and a long lifetime. An organic EL device comprising light emitting layers between an anode and a cathode opposite to each other; wherein at least one of the light emitting layers contains, as a thermally activated delayed fluorescence material, a compound in which a boron-containing electron acceptor backbone is linked with an electron donor backbone having a specific fused ring structure; and the compound is represented by the following general formula (1) where X1 is O or S. Provided is a thermally activated delayed fluorescence organic EL device having high emission efficiency and a long lifetime. An organic EL device comprising light emitting layers between an anode and a cathode opposite to each other; wherein at least one of the light emitting layers contains, as a thermally activated delayed fluorescence material, a compound in which a boron-containing electron acceptor backbone is linked with an electron donor backbone having a specific fused ring structure; and the compound is represented by the following general formula (1) where X1 is O or S.

IPC Classes  ?

• H10K 85/60 - Organic compounds having low molecular weight
• C07F 5/02 - Boron compounds
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

This carbon dioxide separation/conversion device comprises: one or more separation units (10) for separating carbon dioxide from a carbon dioxide-containing gas to obtain a carbon dioxide-enriched gas; a reaction unit (30) that comprises a catalyst for absorbing and converting carbon dioxide in the carbon dioxide-enriched gas, causes absorption of carbon dioxide in the carbon dioxide-enriched gas by the catalyst, and obtains a post-conversion gas including a conversion product from the carbon dioxide absorbed by the catalyst and hydrogen; and a hydrogen delivery unit (40) that delivers hydrogen to the reaction unit (30), wherein the separation unit (10) comprises one or more separation membrane modules including a separation membrane that separates carbon dioxide from a gas containing carbon dioxide, and a separation membrane module connection unit, which is connected to each separation membrane module and includes a carbon dioxide delivery port through which the carbon dioxide-enriched gas is discharged.

IPC Classes  ?

• C01B 32/40 - Carbon monoxide
• B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
• B01D 71/70 - Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only
• C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen

Abstract

The present invention provides an embryo culture method. More specifically, the invention includes culturing an embryo (especially pre-implantation) on a dish having, on the surface thereof, an extracellular matrix layer having a sufficient thickness. The invention enables, for example, development of an embryo into a post-implantation embryo.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissues; Foetal cells or tissues
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms

Abstract

33-R [where R is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, or an organic group (which is not a hydrocarbon group)] around the electrical-discharge region in the plasma device; and continuously discharging gases from the plasma device.

IPC Classes  ?

• C07C 17/35 - Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or halogen atoms in the molecules
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine

Abstract

22, a hydrogen carbonate, and a carbonate. The membrane-electrode assembly (10) comprises: an electrolytic membrane (13); and a cathode catalyst layer (12) that is provided on the electrolytic membrane (13) and that contains a catalyst. In a state in which the cathode electrode (11) and the cathode catalyst layer (12) are in contact with each other, a cathode contact area, which is an area where the cathode catalyst layer (12) is exposed and where the cathode electrode (11) and the material fluid are not in contact with each other or the cathode electrode (11) and the material fluid are in contact with each other, is smaller than a catalyst contact area, which is an area where the material fluid and an exposure portion in which the cathode catalyst layer is exposed are in contact with each other.

IPC Classes  ?

• C25B 9/65 - Means for supplying current; Electrode connections; Electric inter-cell connections
• C25B 1/23 - Carbon monoxide or syngas
• C25B 9/00 - Cells or assemblies of cells; Constructional parts of cells; Assemblies of constructional parts, e.g. electrode-diaphragm assemblies; Process-related cell features
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
• C25B 11/037 - Electrodes made of particles

Abstract

The present invention provides a method which comprises: a carbon dioxide application step in which carbon dioxide is applied to an ionic liquid; and a plasma irradiation step in which carbon dioxide is converted into carbon monoxide by irradiating the ionic liquid, to which carbon dioxide has been applied, with a plasma.

IPC Classes  ?

• C01B 32/40 - Carbon monoxide

Abstract

A photon upconversion composition containing a naphthalene compound substituted with a substituent containing at least one selected from the group consisting of an alkynyl group, a substituted silyl group, a benzene ring, an heteroaromatic ring, a cyano group and a halogen atom can efficiently convert an excitation light into a UV light at a low excitation light intensity.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C07F 7/08 - Compounds having one or more C—Si linkages
• C07C 15/58 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part substituted by unsaturated hydrocarbon radicals polycyclic condensed containing two rings
• C07C 15/20 - Polycyclic condensed hydrocarbons
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System

Abstract

It is desired to develop a method of producing hydrogen peroxide, which is capable of producing hydrogen peroxide with high production efficiency. According to the present invention, provided is a palladium-containing composition comprising palladium particles and a coating agent that coats the surface of the palladium particles, wherein a compound having an O═X structure (wherein X represents any of a phosphorus atom, a sulfur atom, and a carbon atom) is comprised as the coating agent.

IPC Classes  ?

• B01J 31/28 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of the platinum group metals, iron group metals or copper
• C01B 15/029 - Preparation from hydrogen and oxygen
• B01J 35/02 - Solids

Abstract

Provided are a cooling device and a cooler that is capable of causing boiling at a low superheat by suppressing an increase in a boiling starting point. The cooler uses a boiling method for cooling a heating element, and comprises: a container that accommodates a working fluid; a cooling member that is provided inside the container so as to face the surface of the heating element and that is composed of a porous body; and at least one metal fine wire or a metal thin film that is provided between the surface of the heating element and the cooling member, and is configured so as to be able to be heated.

IPC Classes  ?

• F28F 13/02 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by influencing fluid boundary
• H01L 23/427 - Cooling by change of state, e.g. use of heat pipes
• F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

Provided are a cooling member having a favorable cooling effect, a cooler, a cooling device, and a cooling member manufacturing method. The cooling member comprises integrally formed electrolytic metal foils constituted by a double-layer porous material, each layer having different mean pore sizes.

IPC Classes  ?

• H01L 23/427 - Cooling by change of state, e.g. use of heat pipes
• F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
• F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

This pharmaceutical composition for treatment or prevention of fibrotic disease contains nucleic acid that inhibits the expression of mRNA encoding P4HA3. The fibrotic disease may be at least one disease selected from the group consisting of fibrosis, cirrhosis, renal failure, myocardial infarction, and cancer. The present invention provides a method for preventing or treating fibrotic disease, the method including administering an effective amount of the pharmaceutical composition according to the present invention to a subject who has, or is at risk of contracting, fibrotic disease.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 9/127 - Liposomes
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

This lactic acid bacterium for synthesizing a plasmalogen synthesizes a plasmalogen under an aerobic condition.

IPC Classes  ?

• C12N 1/20 - Bacteria; Culture media therefor
• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen

Abstract

Provided is a measurement device for measuring the mass or mass distribution of particles including organic material, said measurement device comprising: a supply means for supplying particles; an irradiation means for irradiating the particles with near infrared light; an imaging means for acquiring data pertaining to the reflectivity of near infrared light reflected from the particles at an m number of specific wavelengths; and a calculation means for calculating the mass of the particles on the basis of the data pertaining to the reflectivity of the near infrared light at the m number of specific wavelengths. Also provided is a measurement method for measuring the mass or mass distribution of particles including organic material, said method comprising the following steps: (a) supplying particles to a measurement device; (b) irradiating the particles with near infrared light and acquiring data pertaining to the reflectivity of near infrared light at an m number of specific wavelengths; and (c) calculating the mass of the particles on the basis of the acquired data.

IPC Classes  ?

• G01N 15/00 - Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
• G01G 9/00 - Methods of, or apparatus for, the determination of weight, not provided for in groups
• G01G 17/00 - Apparatus for, or methods of, weighing material of special form or property
• G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solids; Preparation of samples therefor
• G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light

Abstract

This anticancer drug contains an ATP8B2 inhibitor.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• A61P 35/00 - Antineoplastic agents
• C12Q 1/06 - Quantitative determination
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

A computer 30 receives, for a limited document group 4B as a document group of a specific technical field, a setting operation for an annotation in which a main intrinsic representation tag T1 and a sub intrinsic representation tag T2 are associated with each other, generates annotation data 5 (training data), finely tunes a pre-learning model 6, which is learned in advance by using a large document group 3, according to the annotation data 5, and generates an intrinsic representation extraction model 8 for extracting information about intrinsic representations from documents. Furthermore, the computer 30 receives a target document 2 as an analysis target and extracts information about intrinsic representations from the target document 2 by using the specific representation extraction model 8.

IPC Classes  ?

• G06F 40/216 - Parsing using statistical methods
• G06F 40/295 - Named entity recognition

Abstract

This medical coating agent comprises a polymer including a structural unit (A) derived from an ethylenic unsaturated monomer having a urea bond. The polymer contained in the medical coating agent satisfies Condition (i) in a case where a polymer water-holding state when the peak top of heat absorption due to the melting of ice appears at 0°C is defined as a water saturation state in a DSC curve obtained by letting the polymer absorb water and then heating the polymer at a rate of 5°C/min using a differential scanning calorimeter. Condition (i): The intermediate water amount in the water saturation state is not less than 3.0 mass% with respect to the entire amount of the polymer in the water saturation state.

IPC Classes  ?

• A61L 33/06 - Use of macromolecular materials
• A61L 27/34 - Macromolecular materials
• A61L 29/08 - Materials for coatings
• A61L 31/10 - Macromolecular materials
• C08F 20/34 - Esters containing nitrogen

Abstract

Provided are a luminescent material, and an organic EL element using the luminescent material and having a high luminous efficiency and a long lifespan.　Provided is an organic EL element including a luminescent layer between an anode and a cathode that face one another, wherein a compound, which serves as a luminescent dopant and in which a boron atom and a scaffold having a specific structure are combined, is included in at least one luminescent layer. The compound is represented by general formula (1) or general formula (2).

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C07F 5/02 - Boron compounds
• H10K 50/00 - Organic light-emitting devices

Abstract

A method for producing an olefin sulfide according to the present invention enables the achievement of a dialkyl polysulfide (A) by reacting an olefin compound (a) represented by formula (1) R1R2C=CHR3(wherein each of R1and R2represents an alkyl group; R3represents a hydrogen atom or an alkyl group; and the total number of carbon atoms in R1, R2and R3 is 2 to 20) and sulfur with each other in the presence of hydrogen.

IPC Classes  ?

• C07C 319/22 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
• C07B 61/00 - Other general methods
• C07C 321/14 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
• C10M 135/04 - Hydrocarbons

Abstract

A metal-crosslinkable polymer composition and a metal crosslinked polymeric material having excellent curing rate and storage stability, and a metal member and a wiring harness to which the metal-crosslinkable polymer composition and the metal crosslinked polymeric material are applied. The metal-crosslinkable polymer composition includes an ingredient A which releases a metal ion when heated, and an ingredient B includes an organic polymer having a substituent group capable of forming an ionic bond with the metal ion released from the ingredient A. The metal-crosslinked polymeric material includes a crosslinked product of the metal-crosslinkable polymer composition. The metal member has a metal base member and a coating member covering a surface of the metal base member, where the coating member includes the metal-crosslinked polymeric material. The wiring harness includes the metal-crosslinked polymeric material.

IPC Classes  ?

• C08K 5/00 - Use of organic ingredients
• C08F 36/06 - Butadiene
• C08F 22/06 - Maleic anhydride
• C08L 9/00 - Compositions of homopolymers or copolymers of conjugated diene hydrocarbons

Abstract

Substances present in urinary microvesicles of bladder cancer patients are identified to thereby construct a method of assisting in early and accurate diagnosis of bladder cancer. In the assistant method, microvesicles are enriched, and whether or not the subject patient has bladder cancer is determined depending on the amount of a marker protein present in the microvesicles.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The purpose of the present invention is to provide a heparin-like substance having a high biological activity (anticoagulant activity) as heparin. Provided is a method for producing a heparin-like substance, the method including a step for culturing an animal cell having, introduced therein, the below-mentioned polynucleotides to produce a supernatant containing the heparin-like substance. A polynucleotide encoding bifunctional heparan sulfate N-deacetylase/N-sulfotransferase (NDST2); a polynucleotide encoding heparan sulfate glucosamine 3-sulfotransferase 1 (Hs3st1); a polynucleotide encoding an extracellular domain of syndecan (SDC); and a polynucleotide encoding 6-O-sulfotransferase.

IPC Classes  ?

• C12N 15/54 - Transferases (2)
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

A membrane protein analysis substrate including an electron microscope grid having a plurality of through-holes; a lipid bilayer membrane that is provided to cover at least one of the plurality of through-holes; and membrane proteins that are retained in a part planarly overlapping the through-holes of the lipid bilayer membrane, wherein the lipid bilayer membrane has a lipid monolayer, and wherein the lipid monolayer is larger than the through hole in a plan view, adheres to the grid, and constitutes a part of the lipid bilayer membrane,

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol
• G01N 33/487 - Physical analysis of biological material of liquid biological material

Abstract

Provided is a method for leaching nickel from a nickel oxide ore that enables a nickel sulfate production method which is easily carried out with a small amount of waste generation. The method for leaching nickel into an organic phase disclosed here includes the step of bringing a nickel ore into contact with an organic phase. The organic phase contains a hydrophobic deep eutectic solvent including a hydrogen bond donor and a hydrogen bond acceptor, and an organic acid. The hydrogen bond donor is an acidic hydrogen bond donor. The organic acid is a strong acid.

IPC Classes  ?

• C01G 53/00 - Compounds of nickel
• C01G 53/10 - Sulfates
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions

Abstract

One of the problems addressed by the present invention is to provide a cancer-cell proliferation inhibitor that contains a compound that is derived from a food component and that is highly safe. The description of the present application discloses a cancer-cell proliferation inhibitor that contains an immune checkpoint inhibitor and at least one of 5-(3,5-dihydroxyphenyl)-γ-valerolactone represented by formula (I), a salt of said compound, and a conjugate of said compound.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/365 - Lactones
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Abstract

[Problem to be Solved] To provide a polymer material having cancer cell adhesion properties while having biocompatibility. [Problem to be Solved] To provide a polymer material having cancer cell adhesion properties while having biocompatibility. [Means to Solve the Problem] A composition for cancer cell adhesion according to the present invention comprises a biocompatible copolymer comprising: at least one repeating unit (A) represented by the following formula (1): wherein R1 represents a methyl group or an ethyl group; and at least one repeating unit (B) represented by the following formula (2): wherein R2 represents an aliphatic hydrocarbon group.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• C08F 216/18 - Acyclic compounds

Abstract

This invention includes, e.g., a pharmaceutical composition serving to treat retinitis pigmentosa and containing nanoparticles in which statin is encapsulated.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/10 - Dispersions; Emulsions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/47 - Quinolines; Isoquinolines
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 27/02 - Ophthalmic agents

Abstract

Provided is a catalyst which comprises a compound represented by formula (1) and which exhibits activity for at least one type of reaction selected from among hydrosilylation reaction or hydrogenation reaction with respect to an aliphatic unsaturated bond and hydrosilane reduction reaction with respect to a carbon-oxygen unsaturated bond or a carbon-nitrogen unsaturated bond. Formula (1): Mn(Lm) {M represents Fe, Co, or Ni having an oxidation number of 0, L represents an isocyanide ligand represented by formula (2), n denotes an integer of 1-8, and m denotes an integer of 2-12. Formula (2): (CN)x—R1 (R1 represents a mono- to trivalent-organic group having 1-30 carbon atoms, optionally being substituted by a halogen atom, and optionally having interposed therein one or more atoms selected from among O, N, S, and Si; and x denotes an integer of 1-3)}.

IPC Classes  ?

• B01J 31/22 - Organic complexes
• C07F 7/08 - Compounds having one or more C—Si linkages
• C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen

Abstract

An organic semiconductor laser device with a supercell structure composed of a first short-pitch periodic structure with length WS1, a long-pitch periodic structure with length WL and a second short-pitch periodic structure with length WS2 is improved by lengthening (WS1 + WS2), shortening WL, lengthening (WS1 + WL + WS2), or repeating the supercell structure.

IPC Classes  ?

• H01S 5/36 - Structure or shape of the active region; Materials used for the active region comprising organic materials

Abstract

The present invention provides a primer set for detecting the presence of bladder cancer in a specimen, said primer set containing a pair of primers that are oligonucleotides targeting a PLEKHS1 promoter mutation and having a length of 16-21 bases inclusive, and one or more pairs of primers targeting a TERT promoter mutation.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided is an electrode material for providing a fuel cell electrode having superior electrode performance and durability.　This electrode material is the following electrode material (A) or electrode material (B). Electrode material (A): An electrode material including a porous composite carrier composed of a carbon carrier made of mesoporous carbon and an electron conductive oxide fixed to, among the pore inner surfaces and pore outer surfaces of the mesoporous carbon, at least the pore inner surfaces of the mesoporous carbon, and including electrode catalyst particles carried on the porous composite carrier, wherein some or all of the electrode catalyst particles are carried on the pore inner surfaces of the mesoporous carbon via the electron conductive oxide. Electrode material (B): An electrode material including a carbon carrier made of mesoporous carbon, and an electrode catalyst composite fixed to, among the pore inner surfaces and pore outer surfaces of the mesoporous carbon, at least the pore inner surfaces of the mesoporous carbon, wherein the electrode catalyst composite includes electrode catalyst particles and an electron conductive oxide, and the electron conductive oxide is present so as to fill the gaps between the electrode catalyst particles.

IPC Classes  ?

• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/90 - Selection of catalytic material
• H01M 4/92 - Metals of platinum group
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

11 is an organic group and n is an integer of 2 or larger.

IPC Classes  ?

• C08G 65/26 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
• C08G 65/10 - Saturated oxiranes characterised by the catalysts used
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/02 - Disposition of insulation

Abstract

Provided is an ore dressing method that can obtain a low-arsenic-grade concentrate from a high-arsenic-grade starting material.　The ore dressing method has: a repulping step for obtaining a mineral slurry by adding water to a starting material that contains an arsenic-free sulfide mineral, i.e., a sulfide mineral that does not contain arsenic, and an arsenic-containing sulfide mineral, i.e., a copper sulfide mineral that contains arsenic; a pH adjustment step for adjusting the pH of the liquid phase of the mineral slurry to at least 10; a conditioning step for adding an oxidizing agent and an alkali metal xanthate to the mineral slurry; and a flotation step for carrying out flotation using the mineral slurry to effect separation of the starting material into: a floating ore that has a higher grade of arsenic-free sulfide mineral than the starting material, and a sedimented ore that has a higher grade of arsenic-containing sulfide mineral than the starting material. The starting material contains 4.4-5.8 weight parts of arsenic per 100 weight parts of copper.

IPC Classes  ?

• C22B 1/11 - Removing sulfur, phosphorus or arsenic, other than by roasting
• B03D 1/008 - Organic compounds containing oxygen
• B03D 1/012 - Organic compounds containing sulfur
• C22B 1/00 - Preliminary treatment of ores or scrap
• C22B 15/00 - Obtaining copper
• B03D 101/02 - Collectors
• B03D 103/02 - Ores

Abstract

The purpose of the present invention is to provide a novel material that promotes the production of collagen and/or hyaluronic acid and/or activates human epidermal keratinocytes. A lactic acid bacterium belonging to the genus Fructobacillus, a culture of the lactic acid bacterium, a culture supernatant of the lactic acid bacterium, and/or an extract of the lactic acid bacterium are useful as an active ingredient in a collagen production promotor, a hyaluronic acid production promoter, and an epidermal keratinocyte activator.

IPC Classes  ?

• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/74 - Bacteria
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 27/02 - Ophthalmic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations

Abstract

emTTISCRISCRISC is the reverse intersystem crossing rate from the excited triplet state to the excited singlet state.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 85/30 - Coordination compounds
• H10K 101/20 - Delayed fluorescence emission

Abstract

333, and (8) L-glutamine.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0735 - Embryonic stem cells; Embryonic germ cells

Abstract

Provided is a medical device that can achieve both of biocompatibility and physical properties and contains a polyurethane resin elastomer. The medical device according to an embodiment includes a polyurethane resin elastomer and water contained in the polyurethane resin elastomer. The polyurethane resin elastomer contains polyethylene glycol and a polyisocyanate as constituents thereof, in which the polyethylene glycol has a number average molecular weight of 200 to 2200 inclusive, and the amount of the polyethylene glycol relative to 100% by mass of the constituents of the polyurethane resin elastomer is 1% by mass or more and less than 50% by mass.

IPC Classes  ?

• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 29/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• C08G 18/28 - Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
• C08G 18/44 - Polycarbonates
• C08G 18/48 - Polyethers
• C08G 18/73 - Polyisocyanates or polyisothiocyanates acyclic
• C08G 18/75 - Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
• C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic

Abstract

According to the present invention, an epoxy resin composition that is capable of combining flexibility, toughness, and adhesiveness and that can be dismantled easily by heating, a cured product thereof, and a laminate can be provided. The epoxy resin composition of the present invention contains an epoxy resin (A) having an epoxy equivalent of 500-10,000 g/eq, an epoxy resin (B) having an epoxy equivalent of 100-300 g/eq, and a compound (C) having an anthracene dimer skeleton. The epoxy resin (A) is represented by general formula (1), and the compound (C) has two or more epoxy group-containing groups or two or more curable group-containing groups.

IPC Classes  ?

• C08G 59/40 - Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups characterised by the curing agents used
• B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties
• B32B 27/38 - Layered products essentially comprising synthetic resin comprising epoxy resins
• C08G 59/20 - Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups characterised by the epoxy compounds used
• C09J 163/00 - Adhesives based on epoxy resins; Adhesives based on derivatives of epoxy resins

Abstract

A first object of the present invention is to provide an antithrombotic cell adhesion sheet having excellent antithrombotic properties and cell adhesion properties. In addition, a second object of the present invention is to provide a medical device with a sheet using the antithrombotic cell adhesion sheet. A first object of the present invention is to provide an antithrombotic cell adhesion sheet having excellent antithrombotic properties and cell adhesion properties. In addition, a second object of the present invention is to provide a medical device with a sheet using the antithrombotic cell adhesion sheet. The antithrombotic cell adhesion sheet of the present invention is a sheet formed b using a compound represented by General Formula (1). A first object of the present invention is to provide an antithrombotic cell adhesion sheet having excellent antithrombotic properties and cell adhesion properties. In addition, a second object of the present invention is to provide a medical device with a sheet using the antithrombotic cell adhesion sheet. The antithrombotic cell adhesion sheet of the present invention is a sheet formed b using a compound represented by General Formula (1). A first object of the present invention is to provide an antithrombotic cell adhesion sheet having excellent antithrombotic properties and cell adhesion properties. In addition, a second object of the present invention is to provide a medical device with a sheet using the antithrombotic cell adhesion sheet. The antithrombotic cell adhesion sheet of the present invention is a sheet formed b using a compound represented by General Formula (1). In General Formula (1), R1 and R4 each independently represent a hydrogen atom or a methyl group. R2 and R3 each independently represent —CH2CH(RA1)CH2—. p and r represent 1. q represents 0 or 1. m and n each independently represent an integer of 2 to 6. RA1 represents a hydrogen atom or a methyl group.

IPC Classes  ?

• A61L 33/06 - Use of macromolecular materials
• A61L 31/04 - Macromolecular materials
• A61L 29/04 - Macromolecular materials
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

: The invention provides a sample holder arrangement (1) comprising (i) a 5 collection chamber (100) having an interior space (101), (ii) a sample holding part (3), (iii) an inlet (110), and (iv) an outlet (120); wherein: the inlet (110) is configured for receiving a supercritical fluid (10); the outlet (120) is configured for depressurizing one or more of the interior space (101) and the sample holding part; the sample holding part (3) is detachably configured in the interior space (101); the sample holding part (3) hosts a single crystal of a 0 porous framework (20) such that the single crystal of a porous framework (20) is configured in the interior space (101); and the single crystal of the porous framework (20) is configured in fluid connection with the inlet (110).

IPC Classes  ?

• G01N 23/20025 - Sample holders or supports therefor
• B01D 15/40 - Selective adsorption, e.g. chromatography characterised by the separation mechanism using supercritical fluid as mobile phase or eluent
• G01N 30/84 - Preparation of the fraction to be distributed
• G01N 30/80 - Fraction collectors

Abstract

PNPLA3PNPLA3) gene. The method can include administering to the subject glutathione (GSH) and/or a nucleic acid molecule encoding a component of the ferroptosis pathway (such as GPX4).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 39/02 - Antidotes
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 38/06 - Tripeptides
• A61K 38/44 - Oxidoreductases (1)
• A01N 1/02 - Preservation of living parts

Abstract

This compound is represented by formula (I). (In formula (I), a carbon atom in the glycerol backbone may have a substituent; an oxygen atom bound to R1is represented by *; and R1 is formula (I-1) which may have a substituent.)

IPC Classes  ?

• C07F 9/10 - Phosphatides, e.g. lecithin
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

This transdermal absorption-type patch is provided with a support and an adhesive agent layer laminated on the support. The adhesive agent layer contains: a solid tacrolimus-surfactant composite in which tacrolimus is covered with a surfactant; an oil phase; and an adhesive agent. The solid tacrolimus-surfactant composite forms solid-in-oil type particles dispersed in the oil phase, and is used for the therapy of neurodegenerative disorders.

IPC Classes  ?

• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 9/66 - Sustained or differential release type containing emulsions, dispersions or solutions
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical

Abstract

A compound represented by the formula (1) has excellent lasing properties. G1 and G2 are H or substituent; FL1 and FL2 are represented by the formula (2); BT is represented by the formula (4); and n1, n2 and m are 1 to 5. A compound represented by the formula (1) has excellent lasing properties. G1 and G2 are H or substituent; FL1 and FL2 are represented by the formula (2); BT is represented by the formula (4); and n1, n2 and m are 1 to 5.

IPC Classes  ?

• H01S 3/16 - Solid materials
• C07D 285/14 - Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
• C07D 249/18 - Benzotriazoles
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07F 7/08 - Compounds having one or more C—Si linkages
• C07D 513/04 - Ortho-condensed systems
• C07D 293/10 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials